DGAP-News: SYGNIS Pharma AG: Shareholders support Management proposals at

---------------------------------------------------------------------

Press Release

Shareholders support Management proposals at SYGNIS Pharma's AGM with overwhelming majority

Madrid/Heidelberg, 30 August 2013 - At the Annual General Meeting (AGM) of SYGNIS Pharma AG (Frankfurt: LIO1; ISIN: DE000A1RFM03; Prime Standard) held on 28 August 2013 shareholders representing about 94 percent of the capital approved all proposals of the Management with an overwhelming majority. Main decisions were related to the discharge of the members of the Supervisory and the Management Board for the past Fiscal Year, the election of new members of the Supervisory Board, the change of the trade name of the Company (new trade name will be: SYGNIS AG), as well as the creation of new authorised capital.

Dr. Wolf-Dieter Starp and Mr. Gonzalo Rodriguez-Fraile Daz have left the Supervisory Board. Dr. Cristina Garmendia Mendizbal, chairwoman of the Supervisory Board thanked Dr. Starp and Mr. Gonzalo Rodriguez-Fraile Daz for their work and efforts for SYGNIS Pharma AG. She welcomed Dr. Franz Wilhelm Hopp and Mr. Werner-Friedrich Knuth Schfer as new members of the Supervisory Board.

At the AGM Pilar de la Huerta, CEO/CFO, confirmed expectations that Qiagen will launch first products with QualiPhi(R) by autumn 2013.

For further information please contact:

SYGNIS Pharma AG Pilar de la Huerta CEO/CFO Tel: +34-918063089 Email: pdelahuerta@sygnis.es

About SYGNIS Pharma AG: http://www.sygnis.de

After the merger in 2012 between X-Pol Biotech, specialising in DNA amplification and sequencing, and SYGNIS Pharma AG, listed in the German Stock Exchange (Prime Standard segment, Tick: LIO1; ISIN: DE000A1RFM03), SYGNIS' new mission is to develop and distribute technologies and products from X-Pol, which has a commercial product in the DNA amplification segment, QualiPhi(R) and is currently developing other products in the field of Next Generation Sequencing. .

Read this article:
DGAP-News: SYGNIS Pharma AG: Shareholders support Management proposals at

Related Posts

Comments are closed.